Allergy Therapeutics PLC shares fell on Tuesday, despite securing an additional £5 million in loans, extending its cash runway.
Allergy Therapeutics is a Sussex, England-based biotechnology company which specialises in allergy vaccines.
Its shares were down 14% to 4.01 pence each in London on Tuesday morning. In the past 12 months, the shares have shot up from 1.31p.
Major shareholders SkyGem Acquisition Ltd and Southern Fox Investments Ltd have agreed to provide a further £5 million from an existing loan facility. The facility was first announced in December last year.
Allergy Therapeutics said it now has extended its cash runway into late September.
It noted that there remains a further £12.5 million of uncommitted funding available under the amended loan facility, and it ‘continues to explore further funding options to support its ongoing operations and development pipeline’.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
